Status:
COMPLETED
Neuropsychologic and Immunological Evaluation in Treatment of Thyroid Diseases. Is Selenium Efficient?
Lead Sponsor:
Karolinska Institutet
Conditions:
QoL Before and After 9 Month of Medical Treatment of Graves´Thyrotoxicosis
Potential Effect of Selenium
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
Graves thyrotoxicosis is a common autoimmune disease. Patients suffer at diagnosis from weight loss, increased heart rate and stress intolerance. Some patients have difficulties in regaining quality o...
Detailed Description
In the County of Södermanland we include 44 patients with Graves´thyrotoxicosis. They are treated with methimazole and thyroxin, and randomised to selenium or placebo. Neuropsychological investigation...
Eligibility Criteria
Inclusion
- New diagnose of autoimmune thyrotoxicosis
- biochemically proven with increased thyroxin
- low TSH and elevated TRAb/or positive scintigraphy.
- Age 18 - 55. Willing to participate -
Exclusion
- No previous head trauma,
- No difficulties with swedish language,
- No medication which could affective neuropsychological testing,
- No planned or ongoing pregnancies.
- Normal intellectual capacity.
- No severe ophthalmopathy, or other severe disease
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2014
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT01247077
Start Date
November 1 2008
End Date
April 1 2014
Last Update
March 31 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Jan Calissendorff, Medical clinic, Eskilstuna, Sweden
Eskilstuna, Södermanland County, Sweden, 63188
2
Emil Mikulski
Eskilstuna, Sweden, 63188